ArticleCancer gene therapy2026
Targeting VPS35 increases chemotherapy sensitivity in gastric cancer cells via regulation of the NF-κB signaling pathway.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vacuolar protein sorting-associated protein 35 (VPS35), a core component of the retromer complex, recognizes cytosolic retrieval signals in cargo proteins and mediates intracellular protein transport. Although previous studies have demonstrated that VPS35 promotes the growth and invasion of gastric cancer (GC), its role and mechanisms in GC chemoresistance remain largely uncharacterized. Here, VPS35 is identified as a potential predictive biomarker for chemotherapy response in GC. Clinically relevant chemotherapeutic agents, including 5-fluorouracil and cisplatin, significantly upregulate VPS35 expression, which is inversely associated with chemosensitivity. Functional assays demonstrate that VPS35 overexpression induces chemoresistance in GC cells, whereas VPS35 knockdown enhances tumor sensitivity to drug-induced cytotoxicity. Mechanistically, VPS35 contributes to chemoresistance by facilitating the nuclear translocation of p65 and activating the NF-κB signaling pathway. These findings suggest that VPS35 may serve as a prognostic biomarker and a promising therapeutic target in GC.
Indexed as
Identifiers
42624899What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.